Cardiovascular Systems, Inc. (CSII)

NASDAQ: CSII · IEX Real-Time Price · USD
19.76
0.00 (0.00%)
Mar 20, 2023, 4:00 PM EDT - Market closed
Market Cap 829.11M
Revenue (ttm) 239.84M
Net Income (ttm) -37.87M
Shares Out 41.96M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 455,843
Open 19.74
Previous Close 19.76
Day's Range 19.70 - 19.77
52-Week Range 12.26 - 23.47
Beta 0.75
Analysts Sell
Price Target 17.75 (-10.17%)
Earnings Date May 3, 2023

About CSII

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Co... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 26, 2009
Employees 725
Stock Exchange NASDAQ
Ticker Symbol CSII
Full Company Profile

Financial Performance

In 2022, CSII's revenue was $236.22 million, a decrease of -8.79% compared to the previous year's $258.97 million. Losses were -$36.93 million, 175.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CSII stock is "Sell." The 12-month stock price forecast is $17.75, which is a decrease of -10.17% from the latest price.

Price Target
$17.75
(-10.17% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes

Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).

20 hours ago - Zacks Investment Research

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Cardiovascular Systems, Inc. - CSII

NEW YORK , Feb. 13, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

1 month ago - PRNewsWire

CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular S...

Other symbols: ABT
1 month ago - Business Wire

Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss

With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.

1 month ago - Zacks Investment Research

SHAREHOLDER ALERT: Weiss Law Investigates Cardiovascular Systems, Inc.

NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cardiovascular Systems, Inc. ("Cardiovas...

Other symbols: ABT
1 month ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cardiovascular Systems, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - February 9, 2023) - Rigrodsky Law, P.A. is investigating Cardiovascular Systems, Inc. ("Cardiovascular") (NASDAQ: CSII) regarding possible breaches of fiduciary...

1 month ago - Newsfile Corp

Why Is Cardiovascular Systems (CSII) Stock Up 48% Today?

Cardiovascular Systems (NASDAQ: CSII) stock is rising higher on Thursday following news that Abbott (NYSE: ABT) intends to acquire the company. That deal has Abbott offering to buy Cardiovascular Sy...

1 month ago - InvestorPlace

CSII STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Cardiovascular Systems, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cardiovascular Systems, Inc. (NASDAQ: CSII) to Abbott Laboratories for $20.00 per common ...

1 month ago - Business Wire

Cardiovascular Systems shares jump after deal to be bought by Abbott for $890 million

Cardiovascular Systems CSII, -1.99% shares rose 47% to $19.58 in early premarket trade after Abbott ABT, -1.60% agreed to buy the company for $890 million, or $20 per share. CSI is a leader in devices...

Other symbols: ABT
1 month ago - Market Watch

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto...

1 month ago - Zacks Investment Research

Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients w...

1 month ago - Business Wire

Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays

Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.

2 months ago - Zacks Investment Research

Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, Feb...

2 months ago - Business Wire

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

2 months ago - Business Wire

Cardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.'s Thrombectomy System

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patien...

2 months ago - Business Wire

Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top

The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).

4 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -12.50% and 0.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

4 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Why Is Cardiovascular Systems (CSII) Down 18.9% Since Last Earnings Report?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark

According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.

8 months ago - Zacks Investment Research

Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

8 months ago - Business Wire